Suratno Lulut Ratnoglik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suratno Lulut Ratnoglik has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Adityo Susilo
Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Special Capital Region of Jakarta.
2 shared publications - Ani Ruspitawati
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Arif Syaiful Haq
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Budi Setiawan
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Dwi O. T. L. Handayani
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Eka Yuli Safitri
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications
Latest Publications
- Open Access
Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.
Open AccessEpidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.
- Open Access
- 22 November 2024
- Published by MDPI AG in Preprints.org
Epidemiology and Clinical Features of Mpox in Jakarta
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.
- 22 November 2024
- Published by MDPI AG in Preprints.org
Open AccessEpidemiology and Clinical Features of Mpox in Jakarta
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.
- Open Access
- 1 May 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (3) , 95-100
Evaluation of phagocytic index and haematological parameters of Sida rhombifolia extracts in mice as immunomodulator
Background: Sida rhombifolia was reported to have potential anti-hepatitis C virus activity. Anti-viral activities of plants were also reported to modulate immunity. Objective: This research was conducted by testing the immunomodulating activities of Sida rhombifolia extract. Method: This study evaluated cell viability in HepG2 culture cells to determine the 50% of cell viability. The Immunomodulatory activity was evaluated by examining the phagocytic index value and haematology profile. Result: The results showed that the IC50 Sida rhombifolia was 32.5 μg/mL, while the IC50 of CCl4 as negative control was 16.68 μg/mL. Moreover, 100% of cell viability was observed at ½ IC50 and ¼ IC50 of Sida rhombifolia, indicating no toxic effect from the extract. Immunomodulatory assay found that Sida rhombifolia extract demonstrated an immunostimulant effect. The phagocytic index value of Sida rhombifolia was higher than that of the standard drug (a commercial immunostimulant product). Moreover, the haematology evaluation demonstrated no negative effect on haemoglobin, hematocrit and erythrocyte, which showed no difference in values compared to the normal control and the immunostimulant product. Conclusion: Sida rhombifolia plant extract has the potential as an immunomodulator candidate for treating hepatitis.
- 1 May 2024
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (3) , 95-100
Open AccessEvaluation of phagocytic index and haematological parameters of Sida rhombifolia extracts in mice as immunomodulator
Background: Sida rhombifolia was reported to have potential anti-hepatitis C virus activity. Anti-viral activities of plants were also reported to modulate immunity. Objective: This research was conducted by testing the immunomodulating activities of Sida rhombifolia extract. Method: This study evaluated cell viability in HepG2 culture cells to determine the 50% of cell viability. The Immunomodulatory activity was evaluated by examining the phagocytic index value and haematology profile. Result: The results showed that the IC50 Sida rhombifolia was 32.5 μg/mL, while the IC50 of CCl4 as negative control was 16.68 μg/mL. Moreover, 100% of cell viability was observed at ½ IC50 and ¼ IC50 of Sida rhombifolia, indicating no toxic effect from the extract. Immunomodulatory assay found that Sida rhombifolia extract demonstrated an immunostimulant effect. The phagocytic index value of Sida rhombifolia was higher than that of the standard drug (a commercial immunostimulant product). Moreover, the haematology evaluation demonstrated no negative effect on haemoglobin, hematocrit and erythrocyte, which showed no difference in values compared to the normal control and the immunostimulant product. Conclusion: Sida rhombifolia plant extract has the potential as an immunomodulator candidate for treating hepatitis.